[go: up one dir, main page]

WO2011132051A3 - Tricycle compounds as phosphodiesterase-10 inhibitors - Google Patents

Tricycle compounds as phosphodiesterase-10 inhibitors Download PDF

Info

Publication number
WO2011132051A3
WO2011132051A3 PCT/IB2011/000846 IB2011000846W WO2011132051A3 WO 2011132051 A3 WO2011132051 A3 WO 2011132051A3 IB 2011000846 W IB2011000846 W IB 2011000846W WO 2011132051 A3 WO2011132051 A3 WO 2011132051A3
Authority
WO
WIPO (PCT)
Prior art keywords
phosphodiesterase
inhibitors
tricycle
compounds
tricycle compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2011/000846
Other languages
French (fr)
Other versions
WO2011132051A2 (en
Inventor
Laxmikant Atmaram Gharat
Jitendra Maganbhai Gajera
Neelima Khairatkar-Joshi
Malini Bajpai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ichnos Sciences SA
Original Assignee
Glenmark Pharmaceuticals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Pharmaceuticals SA filed Critical Glenmark Pharmaceuticals SA
Publication of WO2011132051A2 publication Critical patent/WO2011132051A2/en
Publication of WO2011132051A3 publication Critical patent/WO2011132051A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The present invention provides Phosphodiesterase- 10 inhibitors. In particular, tricyclic derivatives described herein are useful as Phosphodiesterase- 10 inhibitors. Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by Phosphodiesterase- 10. (Formula I) (I)
PCT/IB2011/000846 2010-04-19 2011-04-18 Tricycle compounds as phosphodiesterase-10 inhibitors Ceased WO2011132051A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
IN1273MU2010 2010-04-19
IN1273/MUM/2010 2010-04-19
US32929910P 2010-04-29 2010-04-29
US61/329,299 2010-04-29
IN3314/MUM/2010 2010-12-06
IN3314MU2010 2010-12-06

Publications (2)

Publication Number Publication Date
WO2011132051A2 WO2011132051A2 (en) 2011-10-27
WO2011132051A3 true WO2011132051A3 (en) 2012-01-19

Family

ID=44834563

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2011/000846 Ceased WO2011132051A2 (en) 2010-04-19 2011-04-18 Tricycle compounds as phosphodiesterase-10 inhibitors

Country Status (1)

Country Link
WO (1) WO2011132051A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2827724A1 (en) 2011-02-18 2012-08-23 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (pde10a)
WO2014071044A1 (en) 2012-11-01 2014-05-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a)
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
CN103755715B (en) * 2013-12-26 2015-12-09 武汉理工大学 Benzofuro[2,3-c]pyridine compound and its synthesis method
GB201702221D0 (en) 2017-02-10 2017-03-29 Univ Of Sussex Compounds
GB201803340D0 (en) * 2018-03-01 2018-04-18 Univ Of Sussex Compounds
CN108892616B (en) * 2018-08-31 2024-06-07 凯莱英生命科学技术(天津)有限公司 Continuous device for preparing benzaldehyde intermediates and its application
CN110003227B (en) * 2019-04-26 2022-03-11 新乡市润宇新材料科技有限公司 Synthetic method of 2-methyl-8-methoxybenzofuran [2,3-b ] pyridine
CN111499540B (en) * 2020-04-22 2022-09-27 中南民族大学 Method for preparing 2,4,6-trichlorobenzonitrile by ammoxidation method, special catalyst and preparation method
CN115677637B (en) * 2022-09-27 2024-02-23 安徽秀朗新材料科技有限公司 Simple preparation method of 1-bromodibenzofuran
CN117143108B (en) * 2023-08-31 2024-03-19 蒲城欧得新材料有限公司 8-bromo-2-methylbenzofuran [2,3-b ] pyridine and synthetic method
CN117466801A (en) * 2023-11-03 2024-01-30 内蒙古大学 Preparation method of polycyclic aromatic hydrocarbon by introducing aldehyde group into pyrrole perylene bay area

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004037805A1 (en) * 2002-10-23 2004-05-06 Glenmark Pharmaceuticals Ltd. Novel tricyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
WO2004089940A1 (en) * 2003-04-11 2004-10-21 Glenmark Pharmaceuticals S.A. Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
WO2006011024A2 (en) * 2004-07-19 2006-02-02 Glenmark Pharmaceuticals Ltd. New tricyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
WO2006064355A2 (en) * 2004-12-17 2006-06-22 Glenmark Pharmaceuticals S.A. Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders
WO2008032171A1 (en) * 2006-09-11 2008-03-20 Matrix Laboratories Ltd. Dibenzofuran derivatives as inhibitors of pde-4 and pde-10
WO2009081222A1 (en) * 2007-12-21 2009-07-02 Glenmark Pharmaceuticals, S.A. Substituted tricyclic pyridine or pyrimidine vanilloid receptor ligands

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004037805A1 (en) * 2002-10-23 2004-05-06 Glenmark Pharmaceuticals Ltd. Novel tricyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
WO2004089940A1 (en) * 2003-04-11 2004-10-21 Glenmark Pharmaceuticals S.A. Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
WO2006011024A2 (en) * 2004-07-19 2006-02-02 Glenmark Pharmaceuticals Ltd. New tricyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
WO2006064355A2 (en) * 2004-12-17 2006-06-22 Glenmark Pharmaceuticals S.A. Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders
WO2008032171A1 (en) * 2006-09-11 2008-03-20 Matrix Laboratories Ltd. Dibenzofuran derivatives as inhibitors of pde-4 and pde-10
WO2009081222A1 (en) * 2007-12-21 2009-07-02 Glenmark Pharmaceuticals, S.A. Substituted tricyclic pyridine or pyrimidine vanilloid receptor ligands

Also Published As

Publication number Publication date
WO2011132051A2 (en) 2011-10-27

Similar Documents

Publication Publication Date Title
WO2011132051A3 (en) Tricycle compounds as phosphodiesterase-10 inhibitors
WO2009156462A3 (en) Organic compounds
WO2008132139A3 (en) New heterocyclic derivatives useful for the treatment of cns disorders
WO2012125488A8 (en) C4-monomethyl triterpenoid derivatives and methods of use thereof
WO2013163190A8 (en) Dna-pk inhibitors
MX2011008864A (en) Sulfonylated tetrahydroazolopyrazines and their use as medicinal products.
WO2009111653A3 (en) Antiviral therapeutic agents
WO2013049726A3 (en) Processes for making compounds useful as inhibitors of atr kinase
WO2011069063A3 (en) Multicyclic compounds and methods of use thereof
WO2012016186A8 (en) Macrocyclic kinase inhibitors and uses thereof
WO2012118812A3 (en) Substituted 6,5-fused bicyclic heteroaryl compounds
WO2008152099A3 (en) Aryl/hetarylamides as modulators of the ep2 receptor
CA2830549C (en) Methods and compositions for preparing noribogaine from voacangine
WO2012083306A3 (en) Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators
PH12015500211B1 (en) 4-methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes
WO2010129918A8 (en) Triptolide prodrugs
WO2010150211A3 (en) Use of derivatives of indoles for the treatment of cancer
MX2016007128A (en) Ccr6 compounds.
WO2010089327A3 (en) Indole derivatives as anticancer agents
WO2010007482A3 (en) Thiazole derivatives as stearoyl coa desaturase inhibitors
WO2009115084A3 (en) Pyrrolopyrimidine derivatives, and use thereof
WO2013040227A3 (en) Therapeutic compounds
WO2009037542A3 (en) Spirocyclic compounds as stearoyl coa desaturase inhibitors
WO2010049449A3 (en) Novel salts of sunitinib
WO2012162513A3 (en) Alcohol-, diol-, and carbohydrate-substituted indenoisoquinolines as topoisomerase i inhibitors

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11771658

Country of ref document: EP

Kind code of ref document: A2